At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 10, 2026 at 06:00 ET
Esperion Therapeutics reported strong financial results for Q4 and full-year 2025, with total revenue growing 144% YoY in Q4 to $168.4 million and 21% for the full year to $403.1 million. U.S. net product revenue grew 38% YoY in both periods, driven by bempedoic acid franchise momentum. The company also announced an acquisition of Corstasis Therapeutics to expand its cardiovascular portfolio with Enbumyst™, a nasal spray diuretic for heart failure patients.
- Q4 2025 total revenue grew 144% YoY to $168.4 million; full-year 2025 revenue grew 21% to $403.1 million
- Q4 U.S. net product revenue grew ~38% YoY to $43.7 million; full-year U.S. net product revenue grew 38% to $159.6 million
- Q4 retail prescription equivalents grew 34% YoY and 11.3% Q/Q
- Net income of $61.8 million in Q4 2025 vs. net loss of $21.3 million in Q4 2024
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access